NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc.（NGM）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
ngm · 股价预测 · 15 位分析师（近3月）· FMP · 更新于 2025年4月25日
分析师评级与共识
基于过去 3 个月内 15 位华尔街分析师
Buy
15 位分析师
共识
评级分布
12 个月目标价
High
$29.00
Consensus
$16.50
+971.4% upside
Low
$4.00
Median: $16.5 · Last Close: $1.54
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$16.50
971.4% upside
High Target
$29
1783.1%
Low Target
$4
159.7%
Current Price
$1.54
as of today
Based on analyst price targets, the NGM stock price prediction for the next 12 months ranges from $4 to $29. The consensus NGM price forecast of $16.50 implies 971.4% upside from the current price of $1.54.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.54 | ↓ 0.20% |
1-day model range: $1.52–$1.55. Peak: $1.55 (-0.20%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NGM · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-03-12 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2024-02-28 | TD Cowen | Downgrade ↓ | Outperform→Market Perform |
| 2023-11-22 | B. Riley Securities | Maintains | Buy→Buy |
| 2023-05-03 | Citigroup | Maintains | Buy→Buy |
| 2023-03-30 | B. Riley Securities | Maintains | Buy→Buy |
| 2023-03-29 | B. Riley Securities | Maintains | Buy→Buy |
| 2022-11-04 | Raymond James | Maintains | Outperform→Outperform |
| 2022-11-03 | Raymond James | Maintains | Outperform→Outperform |
| 2022-10-18 | Cowen & Co. | Maintains | Outperform→Outperform |
| 2022-10-18 | Raymond James | Downgrade ↓ | Strong Buy→Outperform |
Wall Street analysts have recently issued updated ratings on NGM Biopharmaceuticals, Inc. (NGM) stock. Of the recent 62 rating actions, 2 were upgrades and 13 were downgrades. 15 analysts currently cover NGM.
分析师推荐趋势
NGM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$0M
↓ 99.6% YoY
Revenue Next Year
$0M
↑ 31.6% YoY
EPS This Year
$-1.16
EPS Next Year
$-0.87
↓ 24.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast NGM EPS of $-1.16 for the current fiscal year, based on estimates from 1 analysts. The NGM revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
NGM 股价预测由两类独立数据源支撑：来自 15 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。NGM 的共识目标价为 $16.50（+971.4% 上行空间），分析师共识为 Buy。
NGM 的短期预测（明日）为 $1.54（-0.20%）。
NGM Biopharmaceuticals, Inc. 在 NASDAQ 上市，代码 NGM。NGM 在 2027 年的整体展望偏积极，在覆盖分析师中约 67% 对应 Buy 共识。
常见问题
NGM 预测 · 8 个问题根据 15 位华尔街分析师，NGM 的 12 个月平均目标价为 $16.50，最高 $29.00、最低 $4.00。若有图表，中位目标价可在上方查看。相对当前价 $1.54，隐含约 +971.4% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.